1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300
https://www.cingulate.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 13
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Shane J. Schaffer Pharm.D., PharmD | CEO & Chairman of the Board | 491,96k | N/D | 1975 |
Dr. Laurie A. Myers M.B.A., Ph.D. | Executive VP & COO | 415,17k | N/D | 1957 |
Dr. Matthew N. Brams M.D. | Executive VP & Chief Medical Officer | 244,79k | N/D | 1964 |
Ms. Jennifer L. Callahan CPA | Senior VP & CFO | N/D | N/D | 1971 |
Dr. Raul R. Silva M.D. | Executive VP & Chief Science Officer | N/D | N/D | 1958 |
Thomas Dalton | Vice President of Investor & Public Relations | N/D | N/D | N/D |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
L'ISS Governance QualityScore di Cingulate Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.